Fluorescence in situ hybridization for the BCR-ABL fusion gene in a patient with imatinib mesylate-resistant chronic myelogenous leukaemia in extramedullary blast crisis.
Mori
Takehiko
T
Division of Haematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan. tmori@sc.itc.keio.ac.jp
Yamazaki
Rie
R
Ikeda
Yasuo
Y
Okamoto
Shinichiro
S
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D001752:Blast Crisis / Q000188:drug therapy / Q000235:genetics*; D019008:Drug Resistance, Neoplasm; D017809:Fatal Outcome; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl